This site is intended for Healthcare Professionals only
Recommended Help
Yes, registration is absolutely FREE
It takes less than a minute to create your secure account – you just need to tell us a few details about yourself and create a password.
Please click on the “Forgot my password” link in the login form and follow the instructions.
Please email info@pharmacy-network.co.uk so we can check for you.
Pharmacy Magazine contains a library of high-quality educational e-learning modules, videos and articles to support your ongoing learning.
Yes, we have content suitable for all abilities, with topics covering business management, clinical, practice and OTC. Our aim is to help you keep up to date and develop your skills and knowledge to positively influence patient outcomes and customer experiences.
Yes, you can access all learning at work or at home on any mobile, PC or tablet device
There are three ways you can find relevant content. Firstly, the homepage will display suggestions for you. If you are logged in, we can tailor the content to your particular job role and topics of interest, as well as making it easy for you to see what’s trending. Secondly, you can use the “search” function at the top of the website. Finally, you can click on “explore” in the main menu and browse topics of interest to you.
We have a range of modules and videos ranging from 2 minutes up to 15 minutes. There is something for everyone, even if you are short on time.
Yes. If you see a piece of learning you would like to take, but haven’t got time right now, you can “Bookmark” it for later. Please note you need to have a registered account and be logged in to access this feature.
Yes, logged in members can record their learning outcomes on any piece of content and save them in their learning log. Pharmacists and technicians can do this using recording templates in line with GPhC requirements.
You have to register an account on Pharmacy Magazine and login to access your personal, secure learning log.
It documents all the learning you have recorded, including completed learning, learning in progress and bookmarked learning you have saved to do later.
Yes, pharmacists and pharmacy technicians also have the ability to record and add their own revalidation entries to their learning log in line with GPhC requirements.
Yes, if you record learning on more than one website, it will be displayed in your learning log which is shared across all the accounts you have registered with The Pharmacy Magazine.
Certificates are available at the end of every module, after the assessment questions. They are also accessible via the learning log.
Login and click on “Settings” in your member menu and click on the relevant links to change any of your details. All saved changes take immediate effect.
Yes absolutely. You are able to delete your account at any time but please be aware that by doing so you will also delete any historical learning records you have in your learning log.
You will need to have registered an account to get help. Logged in members can click on the “Helpdesk” link in their Settings and submit a Helpdesk ticket. We endeavour to respond to new Helpdesk tickets within 24 hours during office hours (9pm to 5pm Mon to Fri)
You can click on the relevant links in the footer of the website. If there are any proposed changes to any of our Policies, we will email registered members in advance.
Yes we are and we take your privacy and the security of your data extremely seriously. Please read the Privacy Policy for further details. Logged in members can click on the “My data” link in “Settings” to download a copy of all the personal data we currently hold on you.
Communications International Group Limited (CIG), the largest, most experienced publisher in the UK pharmacy sector. CIG is the UK’s leading provider of sector-specific news and training, publishing 15 healthcare and beauty titles including Pharmacy Magazine, Training Matters, P3Pharmacy, Independent Community Pharmacist and Beauty Magazine. Over the years the company has built an enviable reputation in pharmacy, journalism, education, training, regulatory, awards and conferences, that today amounts to more than 350 years of healthcare industry experience.
Click on the Sign Out link that can be found at the top of the website, in you member menu.
All of the resources below are designed to help you support and advise customers affected by erection problems. The content is divided by job role and includes everything from short videos to more in-depth learning, making it easy to find something to suit your learning needs.
Essential information can be found at the bottom of this page.
The recommended dose of VIAGRA CONNECT is one 50mg tablet with water, approximately one hour before sexual activity. The maximum recommended frequency is once per day.1 Tadalafil 10mg, the other OTC medication for EPs, is not recommended for continuous daily use.2 Men who use these tablets frequently (i.e. at least twice weekly) should consult their doctor to discuss whether a once daily regimen with the lowest doses of tadalafil would be more suitable.2
Find out moreVIAGRA CONNECT can get to work in as little as 25 minutes and requires sexual stimulation to work.1 However, several factors may affect how effective VIAGRA CONNECT is; it may take longer to work after a high-fat meal and it may be less effective after excessive alcohol consumption.2
Learn more74% of men report improved erections with VIAGRA CONNECT;1 however, some men may need several attempts at different times before seeing an improvement. Some reasons for treatment failure include not having adequate sexual stimulation or not waiting an adequate amount of time between taking the medication and attempting intercourse.2
Find out moreComplete the activities in this interactive module in order to understand your EP customers better, so you can offer them optimal support
Start now!E-learning and videos to help improve your understanding and advice on erection problems
Download these documents to further your knowledge
The blue diamond and VIAGRA CONNECT® are registered trademarks of Viatris UK Healthcare Limited. ® 2024. All rights reserved.
Content developed by Viatris UK Healthcare Limited working together with CIG Healthcare Partnership. ® 2024 CIG Healthcare Partnership
Long form Essential Information
Name of product: VIAGRA CONNECT® 50 mg Film-coated Tablets
Active ingredient: Sildenafil
Product licence number: PL 50622/0063
Name and address of the product licence holder: Upjohn UK Limited,
Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK
Supply classification: P
Indications: For erectile dysfunction in adult men.
Side Effects: The safety profile of VIAGRA is based on > 9,000
patients in > 70 double-blind placebo controlled clinical studies. The most commonly
reported adverse reactions in clinical studies among sildenafil treated patients were
headache, flushing, dyspepsia, nasal congestion, dizziness, nausea, hot flush, visual
disturbance, cyanopsia and vision blurred. Adverse reactions from post marketing
surveillance has been gathered covering an estimated period >10 years. Because not
all adverse reactions are reported to the Marketing Authorisation Holder and included in
the safety database, the frequencies of these reactions cannot be reliably determined.
Very Common (≥ 1/10): Headache. Common (≥ 1/100 and <1/10): Dizziness, Visual
colour distortions (Chloropsia, Chromatopsia, Cyanopsia, Erythropsia and Xanthopsia),
Visual disturbance, Vision blurred, Flushing, Hot flush, Nasal congestion, Nausea,
Dyspepsia. Uncommon (≥ 1/1,000 and <1/100): Rhinitis, Hypersensitivity;
Somnolence; Hypoaesthesia, Lacrimation disorders (Dry eye, Lacrimal disorder and
Lacrimation increased), Eye pain, Photophobia, Photopsia, Ocular hyperaemia, Visual
brightness, Conjunctivitis, Vertigo, Tinnitus, Tachycardia, Palpitations, Hypertension,
Hypotension, Epistaxis, Sinus congestion, Gastro Oesophagael reflux disease, Vomiting,
Abdominal pain upper, Dry mouth, Rash, Myalgia, Pain in extremity, Haematuria, Chest
pain, Fatigue, Feeling hot, Heart rate increased. Rare (≥ 1/10,000 and <1/1,000):
Cerebrovascular accident, Transient ischaemic attack, Seizure, Seizure recurrence,
Syncope, Non-arteritic anterior ischaemic optic neuropathy (NAION), Retinal vascular
occlusion, Retinal haemorrhage, Arteriosclerotic retinopathy, Retinal disorder,
Glaucoma, Visual field defect, Diplopia, Visual acuity reduced, Myopia, Asthenopia,
Vitreous floaters, Iris disorder, Mydriasis, Halo vision, Eye oedema, Eye swelling, Eye
disorder, Conjunctival hyperaemia, Eye irritation, Abnormal sensation in eye, Eyelid
oedema, Scleral discoloration, Deafness, Sudden cardiac death, Myocardial infarction,
Ventricular arrhythmia, Atrial fibrillation, Unstable angina, Throat tightness, Nasal
oedema, Nasal dryness, Hypoaesthesia oral, Stevens-Johnson Syndrome (SJS), Toxic
Epidermal Necrolysis (TEN),Penile haemorrhage, Priapism, Haematospermia, Erection
increased, Irritability
Precautions: Erectile dysfunction can be associated with a number of
contributing conditions, e.g. hypertension, diabetes mellitus, hypercholesterolaemia or
cardiovascular disease. As a result, all men with erectile dysfunction should be advised
to consult their doctor within 6 months for a clinical review of potential underlying
conditions and risk factors associated with erectile dysfunction (ED). If symptoms of ED
have not improved after taking VIAGRA CONNECT on several consecutive occasions, or if
their erectile dysfunction worsens, the patient should be advised to consult their
doctor.
Cardiovascular risk factors: Since there is a degree of cardiac risk associated with
sexual activity, the cardiovascular status of men should be considered prior to
initiation of therapy. Agents for the treatment of erectile dysfunction, including
sildenafil, are not recommended to be used by those men who with light or moderate
physical activity, such as walking briskly for 20 minutes or climbing 2 flights of
stairs, feel very breathless or experience chest pain. The following patients are
considered at low cardiovascular risk from sexual activity: patients who have been
successfully revascularised (e.g. via coronary artery bypass grafting, stenting, or
angioplasty), patients with asymptomatic controlled hypertension, and those with mild
valvular disease. These patients may be suitable for treatment but should consult a
doctor before resuming sexual activity.
Patients previously diagnosed with the following must be advised to consult with their
doctor before resuming sexual activity: uncontrolled hypertension, moderate to severe
valvular disease, left ventricular dysfunction, hypertrophic obstructive and other
cardiomyopathies, or significant arrhythmias. Sildenafil has vasodilator properties,
resulting in mild and transient decreases in blood pressure. Patients with increased
susceptibility to vasodilators include those with left ventricular outflow obstruction
(e.g., aortic stenosis), or those with the rare syndrome of multiple system atrophy
manifesting as severely impaired autonomic control of blood pressure. Men with these
conditions must not use the product without consulting a doctor. Sildenafil potentiates
the hypotensive effect of nitrates (see Contra-indications). Serious
cardiovascular events, including myocardial infarction, unstable angina, sudden cardiac
death, ventricular arrhythmia, cerebrovascular haemorrhage, transient ischaemic attack,
hypertension and hypotension have been reported post-marketing in temporal association
with the use of sildenafil. Most, but not all, of these patients had pre-existing
cardiovascular risk factors. Many events were reported to occur during or shortly after
sexual intercourse and a few were reported to occur shortly after the use of sildenafil
without sexual activity. It is not possible to determine whether these events are
related directly to these factors or to other factors. Priapism:
Patients who have conditions which may predispose them to priapism (such as sickle cell
anaemia, multiple myeloma or leukaemia), should consult a doctor before using agents for
the treatment of erectile dysfunction, including sildenafil. Prolonged erections and
priapism have been occasionally reported with sildenafil in post-marketing experience.
In the event of an erection that persists longer than 4 hours, the patient should seek
immediate medical assistance. If priapism is not treated immediately, penile tissue
damage and permanent loss of potency could result. Concomitant use with other treatments
for erectile dysfunction: The safety and efficacy of combinations of sildenafil with
other treatments for erectile dysfunction have not been studied. Therefore the use of
such combinations is not recommended. Effects on vision: Cases of visual defects have
been reported spontaneously in connection with the intake of sildenafil and other PDE5
inhibitors (see Side Effects). Cases of non-arteritic anterior
ischaemic optic neuropathy, a rare condition, have been reported spontaneously and in an
observational study in connection with the intake of sildenafil and other PDE5
inhibitors (see Side Effects). Patients should be advised that in the
event of any sudden visual defect, they should stop taking VIAGRA CONNECT and consult a
physician immediately (see Contra-indications). Concomitant use with
CYP3A4 inhibitors: Pharmacokinetic analysis of clinical trial data indicated a reduction
in sildenafil clearance when co-administered with CYP3A4 inhibitors (such as
ketoconazole, itraconazole, erythromycin, cimetidine). Although, no increased incidence
of adverse events was observed in these patients, they should be advised to consult a
doctor before taking VIAGRA CONNECT as a 25 mg tablet may be more suitable for them (see
Precautions). Concomitant use with alpha-blockers: Caution is advised
when sildenafil is administered to patients taking an alpha-blocker, as the
co-administration may lead to symptomatic hypotension in a few susceptible individuals
(see Precautions). This is most likely to occur within 4 hours post
sildenafil dosing. In order to minimise the potential for developing postural
hypotension, patients should be hemodynamically stable on alpha-blocker therapy prior to
initiating sildenafil treatment. Thus, patients taking alpha blockers should be advised
to consult their doctor before taking VIAGRA CONNECT as a 25 mg tablet may be more
suitable for them. Treatment should be stopped if symptoms of postural hypotension
occur, and patients should seek advice from their doctor on what to do. Effect on
bleeding: Studies with human platelets indicate that sildenafil potentiates the
antiaggregatory effect of sodium nitroprusside in vitro. There is no safety information
on the administration of sildenafil to patients with bleeding disorders or active peptic
ulceration. Therefore the use of sildenafil is not recommended in those patients with
history of bleeding disorders or active peptic ulceration, and should only be
administered after consultation with a doctor. Hepatic impairment: Patients with hepatic
impairment must be advised to consult their doctor before taking VIAGRA CONNECT, since a
25 mg tablet may be more suitable for them (see Dosage and Method of
use). Renal impairment: Patients with severe renal impairment (creatinine
clearance <30 mL/min), must be advised to consult their doctor before taking VIAGRA
CONNECT, since a 25 mg tablet may be more suitable for them (see Dosage and
Method of use). Lactose: The film coating of the tablet contains lactose.
VIAGRA CONNECT should not be administered to men with rare hereditary problems of
galactose intolerance, total lactase deficiency or glucose-galactose malabsorption.
Sodium: This medicinal product contains less than 1 mmol sodium (23 mg) per tablet.
Patients on low sodium diets can be informed that this medicinal product is essentially
‘sodium-free’. Use with alcohol Drinking excessive alcohol can temporarily
reduce a man’s ability to get an erection. Men should be advised not to drink
large amounts of alcohol before sexual activity.
Contra-indications: Hypersensitivity to the active substance or to any
of the excipients listed in section 6.1. Consistent with its known effects on the nitric
oxide/cyclic guanosine monophosphate (cGMP) pathway, sildenafil was shown to potentiate
the hypotensive effects of nitrates, and its co-administration with nitric oxide donors
(such as amyl nitrite) or nitrates in any form is therefore contraindicated.
Co-administration of VIAGRA CONNECT with ritonavir (a highly potent P450 enzyme
inhibitor) is contraindicated (see Precautions). The co-administration
of phosphodiesterase type 5 (PDE5) inhibitors, including sildenafil, with guanylate
cyclase stimulators, such as riociguat, is contraindicated as it may potentially lead to
symptomatic hypotension (see Precautions). Agents for the treatment of
erectile dysfunction, including sildenafil, should not be used by those men for whom
sexual activity may be inadvisable, and these patients should be referred to their
doctor. This includes patients with severe cardiovascular disorders such as a recent (6
months) acute myocardial infarction (AMI) or stroke, unstable angina or severe cardiac
failure. Sildenafil should not be used in patients with severe hepatic impairment,
hypotension (blood pressure < 90/50 mmHg) and known hereditary degenerative retinal
disorders such as retinitis pigmentosa (a minority of these patients have genetic
disorders of retinal phosphodiesterases). This is because the safety of sildenafil has
not been studied in these sub-groups of patients, and its use is therefore
contraindicated. Sildenafil is contraindicated in patients who have loss of vision in
one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless
of whether this episode was in connection or not with previous PDE5 inhibitor exposure.
VIAGRA CONNECT should not be used in patients with anatomical deformation of the penis
(such as angulation, cavernosal fibrosis or Peyronie's disease). VIAGRA CONNECT is
not indicated for use by women. The product is not intended for men without erectile
dysfunction. This product is not intended for men under 18 years of age.
Dosage and Method of use: For Oral Use: Adults: The recommended dose is
one 50 mg tablet taken with water approximately one hour before sexual activity. The
maximum recommended dosing frequency is once per day. If VIAGRA CONNECT is taken with
food, the onset of activity may be delayed compared to the fasted state. Patients should
be advised that they may need to take VIAGRA CONNECT a number of times on different
occasions (a maximum of one 50 mg tablet per day), before they can achieve a penile
erection satisfactory for sexual activity. If after several attempts on different dosing
occasions patients are still not able to achieve a penile erection sufficient for
satisfactory sexual activity, they should be advised to consult a doctor. Elderly:
Dosage adjustments are not required in elderly patients (≥ 65 years old). Renal
Impairment: No dosage adjustments are required for patients with mild to moderate renal
impairment. However, since sildenafil clearance is reduced in individuals with severe
renal impairment (creatinine clearance <30ml/min), individuals previously diagnosed
with severe renal impairment must be advised to consult their doctor before taking
VIAGRA CONNECT, since a 25 mg tablet may be more suitable for them (see Precautions).
Hepatic Impairment: Sildenafil clearance is reduced in individuals with hepatic
impairment (e.g. cirrhosis). Individuals previously diagnosed with mild to moderate
hepatic impairment must be advised to consult their doctor before taking VIAGRA CONNECT,
since a 25 mg tablet may be more suitable for them (see Precautions).
The safety of sildenafil has not been studied in patients with severe hepatic
impairment, and its use is therefore contraindicated (see
Contra-indications). Paediatric population: VIAGRA CONNECT is not
indicated for individuals below 18 years of age. Use in patients taking other medicinal
products: Pharmacokinetic analysis of clinical trial data indicated a reduction in
sildenafil clearance when co-administered with CYP3A4 inhibitors (such as ritonavir,
ketoconazole, itraconazole, erythromycin, cimetidine). With the exception of ritonavir,
for which co-administration with sildenafil is contraindicated (see Contra-indications),
individuals receiving concomitant treatment with CYP3A4 inhibitors must be advised to
consult their doctor before taking VIAGRA CONNECT, since a 25 mg tablet may be more
suitable for them (see Precautions). In order to minimise the potential
of developing postural hypotension in patients receiving alpha blocker treatment (e.g.
alfuzosin, doxazosin or tamsulosin), patients should be stabilised on alpha blocker
therapy prior to initiating sildenafil treatment. Thus, patients taking alpha blockers
must be advised to consult their doctor before taking VIAGRA CONNECT since a 25 mg
tablet may be more suitable for them (see Precautions). Addition of a
single dose of sildenafil to sacubitril/valsartan at steady state in patients with
hypertension was associated with a significantly greater blood pressure reduction
compared to administration of sacubitril/valsartan alone. Therefore, caution should be
exercised when sildenafil is initiated in patients treated with sacubitril/valsartan.
C+D Trade Price (exc VAT) 2 pack £8.82, 4 pack £16.17 and 8
pack £28.39
Date of revision: 04/2023
Please continue to report suspected adverse drug reactions with any medicine or vaccine
to the MHRA through the Yellow Card Scheme. It is easiest and quickest to report adverse
drug reactions online via the Yellow Card website: https://yellowcard.mhra.gov.uk/
or search for MHRA Yellow Card in the Google Play or Apple App Store. Alternatively, you
can report via some clinical IT systems (EMIS/SystmOne/Vision/MiDatabank) or by calling
the Commission on Human Medicines (CHM) free phone line: 0800-731-6789. Adverse
reactions/events should also be reported to MAH at e-mail address: pv.uk@viatris.com.The
SmPC for this product, including adverse reactions, precautions, contra-indications, and
method of use can be found at: Â http://www.mhra.gov.uk/Safetyinformation/Medicinesinformation/SPCandPILs/index.htm
and from Viatris Medical Information, Building 4, Trident Place, Hatfield Business Park,
Mosquito Way, Hatfield, Hertfordshire, AL10 9UL, phone no. 01707 853000, Email: info.uk@viatris.com
Short form Essential Information
Name of product: VIAGRA CONNECT® 50 mg Film-coated Tablets
Active ingredient: Sildenafil
Name and address of the product licence holder: Upjohn UK Limited,
Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK
Supply classification: P
Indications: For erectile dysfunction in adult men.
Further information about this product, including adverse reactions,
precautions, contra-indications, and method of use can be found at: https://www.medicines.org.uk/emc/product/8725
Â